How should a patient taper 300 mg of Luvox (fluvoxamine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

How to Taper Off 300 mg of Luvox (Fluvoxamine)

Taper fluvoxamine gradually by reducing the dose in small increments (approximately 25-50 mg) every 1-2 weeks, monitoring closely for discontinuation symptoms, as fluvoxamine is specifically associated with discontinuation syndrome among SSRIs.

Why Gradual Tapering is Critical

Fluvoxamine is explicitly identified as one of the SSRIs with higher risk for discontinuation syndrome 1. Abrupt discontinuation or missed doses can trigger withdrawal symptoms including dizziness, fatigue, lethargy, general malaise, myalgias, chills, headaches, nausea, vomiting, diarrhea, insomnia, imbalance, vertigo, sensory disturbances, paresthesias, anxiety, irritability, and agitation 1.

The FDA label acknowledges that "symptoms associated with discontinuation of other SSRIs or SNRIs have been reported" and advises clinicians to be aware of this risk 2.

Recommended Tapering Schedule

Starting from 300 mg Daily:

  • Week 1-2: Reduce to 250 mg daily (50 mg reduction)
  • Week 3-4: Reduce to 200 mg daily (50 mg reduction)
  • Week 5-6: Reduce to 150 mg daily (50 mg reduction)
  • Week 7-8: Reduce to 100 mg daily (50 mg reduction)
  • Week 9-10: Reduce to 75 mg daily (25 mg reduction)
  • Week 11-12: Reduce to 50 mg daily (25 mg reduction)
  • Week 13-14: Reduce to 25 mg daily (25 mg reduction)
  • Week 15+: Discontinue or extend interval between doses before stopping

This approach mirrors the general principle from insomnia medication tapering guidelines that recommend "gradually tapering both the dose and frequency of administration" with "the dose lowered by the smallest increment possible in successive steps of at least several days' duration" 3.

Alternative Slower Taper

If the patient experiences significant withdrawal symptoms, slow the taper to 10% of the original dose per month (approximately 30 mg reductions monthly), as this may be better tolerated, particularly for patients on long-term therapy 4.

Key Monitoring Points

Watch for discontinuation symptoms at each dose reduction:

  • Physical symptoms: dizziness, vertigo, sensory disturbances, paresthesias, headaches, nausea, vomiting, diarrhea, myalgias, chills, fatigue
  • Neuropsychiatric symptoms: anxiety, irritability, agitation, insomnia, imbalance
  • Timing: Symptoms typically emerge within 24-48 hours after dose reduction 1

If withdrawal symptoms occur:

  • Return to the previous dose where patient was stable
  • Wait 1-2 weeks for symptom resolution
  • Resume tapering at a slower rate (smaller decrements or longer intervals)

Special Considerations

Fluvoxamine's Pharmacokinetics

Fluvoxamine has a mean half-life of approximately 15.6 hours at steady state 2, making it a shorter-acting SSRI. This shorter half-life contributes to its higher risk for discontinuation syndrome compared to longer-acting agents like fluoxetine 1.

Dosing Logistics

  • If doses above 100 mg were split twice daily, maintain the divided dosing schedule during tapering
  • Give the larger portion at bedtime if doses are unequal 2
  • Once reaching 50 mg or less, can transition to once-daily dosing at bedtime

When to Pause or Slow the Taper

  • Emergence of significant withdrawal symptoms
  • Return of underlying anxiety or OCD symptoms
  • Life stressors that may complicate discontinuation
  • Patient request for slower pace

Common Pitfalls to Avoid

  1. Tapering too quickly: The 1-2 week interval between reductions is a minimum; some patients require longer
  2. Ignoring early withdrawal symptoms: Address symptoms promptly by slowing or pausing the taper rather than pushing through
  3. Abrupt discontinuation: Never stop fluvoxamine suddenly from 300 mg
  4. Inadequate patient education: Patients must understand expected withdrawal symptoms versus relapse of underlying condition

Cognitive-Behavioral Therapy Support

Consider concurrent CBT during the taper, as behavioral therapies can increase successful discontinuation rates and help manage anxiety that may emerge during dose reduction 5.

Timeline Expectations

A complete taper from 300 mg will typically require 3-4 months minimum using the standard approach, or up to 10 months if using the slower 10% monthly reduction strategy. Successful tapering "may require several weeks to months" 3, and this extended timeline is appropriate given the high dose and discontinuation risk profile of fluvoxamine.

References

Guideline

clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders.

Journal of the American Academy of Child and Adolescent Psychiatry, 2020

Guideline

clinical guideline for the evaluation and management of chronic insomnia in adults.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2008

Guideline

prevention and control of seasonal influenza with vaccines.

MMWR Recommendations and Reports, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.